Medical Advanced Technology

Mission — Phys Chem Toxicity Assessment Sys Adv Tech source

This Project covers the development of products and solutions that will protect and prevent degradation of Soldier health, readiness and performance from environmental stressors (heat, cold, altitude, and chemical toxicants) while conducting prolonged operations in Multi-Domain Operations (MDO). Develop algorithms and physiological models to inform unit leaders and Soldiers and provide actionable information and interventions to manage metabolic needs, maintain performance, and avoid non-battle injuries while operating in extreme environments. This Project contains no duplication with any effort within the Military Departments and includes direct participation by other Services. The cited research is fully coordinated with Program Element (PE) 0602143A (Soldier Lethality Technology) and complimentary to PE 0603118A (Soldier Lethality Advanced Technology). The cited research is consistent with the Under Secretary of Defense, Research and Engineering Science and Technology, focus areas and the Army Modernization Strategy.

Mission — MEDICAL ADVANCE TECHNOLOGY INITIATIVES (CA) source

Congressional Interest Item funding for Medical Advanced Technology Initiatives. The cited work is consistent with the Under Secretary of Defense for Research and Engineering priority focus areas and the Army Modernization Strategy.

Mission — Medical Advanced Technology source

This Program Element (PE) matures and demonstrates advanced medical technologies including drugs, medical devices, and developing medical practices and procedures to effectively protect and improve the survivability of United States Forces across the entire spectrum of military operations. Successful completion of efforts relies on tri-Service coordination and cooperation. Promising medical technologies are refined and validated through extensive testing, which is conducted in compliance with Food and Drug Administration (FDA) regulations for human medical products, and Environmental Protection Agency (EPA) regulations for insect-control products that impact humans or the environment (e.g., repellents and insecticides). The FDA requires medical products to undergo extensive preclinical testing in animals and/or other models to obtain preliminary effectiveness and safety information before they can be tested in human clinical trials. Clinical trials are conducted stepwise: first to prove the product is safe in humans, second to demonstrate the desired effectiveness and optimal dosage (amount to be administered) in a small group human study, and third to demonstrate effectiveness in large, diverse human populations. Each successive phase includes larger numbers of human subjects and requires FDA cognizance prior to proceeding. Work conducted in this PE primarily focuses on late stages of technology maturation activities required to conduct safety and effectiveness clinical trials. Some high-risk technologies may require additional maturation with FDA guidance prior to initiating these clinical trials. Such things as proof of product stability and purity are necessary to meet FDA standards before entering later stages of testing and prior to transitioning into a formal acquisition program where large pivotal trials in diverse populations will be conducted for licensure. Activities in this PE may include completion of preclinical animal studies and small safety and effectiveness studies involving humans according to FDA and EPA requirements. Promising medical technologies that are not regulated by the FDA or EPA are modeled, prototyped, and tested in relevant environments. Blast research and research into maturing field rations in this PE are fully coordinated with the United States Army Combat Capabilities Development Command Soldier Center. This coordination enables improved body armor design and rations for Soldiers. Additionally, the activities funded in this PE are externally peer reviewed and fully coordinated with all Services as well as other agencies through the Joint Technology Coordinating Groups of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Community of Interest (COI). The ASBREM COI, formed under the authority of the Under Secretary of Defense for Research and Engineering, serves to facilitate coordination and prevent unnecessary duplication of effort within the Department of Defense's biomedical research and development community, as well as its associated enabling research areas. The cited research is consistent with the Under Secretary of Defense (Research and Engineering) Science and Technology (S&T) focus areas and the Army Modernization Strategy. The FY 2026 request was reduced by $0.059 million for Advisory and Assistance Services to promote efficiencies and advance the policies of the Administration in alignment with Executive Order 14222, "Implementing the President's Department of Government Efficiency Cost Efficiency Initiative." The FY 2026 request was reduced by $0.01 million for civilian personnel to optimize the workforce in compliance with Executive Order 14210, "Implementing the President's Department of Government Efficiency Workforce Optimization Initiative."

Mission — Enabling Med Cap to Support Dispersed OPS Adv Tech source

Matures and demonstrates a tele-monitored and remote-controlled Combat Evacuation Mission Module to support medical resupply and casualty evacuation using future multi-purpose Vertical Take-Off and Landing (VTOL) unmanned aircraft systems (UAS). Provides a self-contained medical module capability adaptable to various future multi- purpose VTOL UAS. Matures and demonstrates an intelligent decision-support capability that can be operated on an Army or Navy provided End User Device (EUD), such as the NETT Warrior system, to assist medics with patient assessment, triage, treatment, and disposition in a Prolonged Field Care (PFC) environment by assessing patient conditions to provide adaptive care guidelines.

Mission — Musculoskeletal Injury Screening Tool Adv Tech source

This Project develops strategies and technologies to reduce musculoskeletal injury (MSKI) rates and improve outcomes following Return to Duty (RTD) in the Army training, operational, and medical communities to improve Soldier readiness. This research will inform the development of technologies and strategies to detect and provide actionable information to unit leader/Soldier about hazardous exposure to blast and head impact. This capability will help prevent degradation to Soldier cognitive readiness and performance and enhance combat power. The cited research is fully coordinated with Program Element (PE) 0602143A (Soldier Lethality Technology) and complimentary to PE 0603118A (Soldier Lethality Advanced Technology) and is fully coordinated with the Army Training and Doctrine Command (TRADOC) and other Services in order to avoid duplication of effort. The cited work is consistent with the Under Secretary of Defense (Research and Engineering) science and technology focus areas and the Army Modernization Strategy.

Mission — Expeditionary Performance Nutrition Advanced Techn source

This Project covers the development of real-time, specific, and individualized interventions to optimize mental acuity and fatigue and manage metabolic and nutritional needs to sustain Soldier physical, mental, and immunological performance. The cited research is fully coordinated with Program element (PE) 0602143A (Soldier Lethality Technology) and complimentary to PE 0603118A (Soldier Lethality Advanced Technology) and is fully coordinated with other Services in order to avoid duplication of effort. The cited research is consistent with the Under Secretary of Defense (Research and Engineering) science and technology focus areas and the Army Modernization Strategy.

Mission — Musculoskeletal Injury Screening Tool Adv Tech source

This Project develops strategies and technologies to reduce musculoskeletal injury (MSKI) rates and improve outcomes following Return to Duty (RTD) in the Army training, operational, and medical communities to improve Soldier readiness. This research will inform the development of technologies and strategies to detect and provide actionable information to unit leader/Soldier about hazardous exposure to blast and head impact. This capability will help prevent degradation to Soldier cognitive readiness and performance and enhance combat power. The cited research is fully coordinated with Program Element (PE) 0602143A (Soldier Lethality Technology) and complimentary to PE 0603118A (Soldier Lethality Advanced Technology) and is fully coordinated with the Army Training and Doctrine Command (TRADOC) and other Services in order to avoid duplication of effort. The cited work is consistent with the Under Secretary of Defense (Research and Engineering) science and technology focus areas and the Army Modernization Strategy.

Mission — Medical Advanced Technology source

This Program Element (PE) matures and demonstrates advanced medical technologies including drugs, medical devices, and developing medical practices and procedures to effectively protect and improve the survivability of United States Forces across the entire spectrum of military operations. Successful completion of efforts relies on tri-Service coordination and cooperation. Promising medical technologies are refined and validated through extensive testing, which is conducted in compliance with Food and Drug Administration (FDA) regulations for human medical products, and Environmental Protection Agency (EPA) regulations for insect-control products that impact humans or the environment (e.g., repellents and insecticides). The FDA requires medical products to undergo extensive preclinical testing in animals and/or other models to obtain preliminary effectiveness and safety information before they can be tested in human clinical trials. Clinical trials are conducted stepwise: first to prove the product is safe in humans, second to demonstrate the desired effectiveness and optimal dosage (amount to be administered) in a small group human study, and third to demonstrate effectiveness in large, diverse human populations. Each successive phase includes larger numbers of human subjects and requires FDA cognizance prior to proceeding. Work conducted in this PE primarily focuses on late stages of technology maturation activities required to conduct safety and effectiveness clinical trials. Some high-risk technologies may require additional maturation with FDA guidance prior to initiating these clinical trials. Such things as proof of product stability and purity are necessary to meet FDA standards before entering later stages of testing and prior to transitioning into a formal acquisition program where large pivotal trials in diverse populations will be conducted for licensure. Activities in this PE may include completion of preclinical animal studies and small safety and effectiveness studies involving humans according to FDA and EPA requirements. Promising medical technologies that are not regulated by the FDA or EPA are modeled, prototyped, and tested in relevant environments. Blast research and research into maturing field rations in this PE are fully coordinated with the United States Army Combat Capabilities Development Command Soldier Center. This coordination enables improved body armor design and rations for Soldiers. Additionally, the activities funded in this PE are externally peer reviewed and fully coordinated with all Services as well as other agencies through the Joint Technology Coordinating Groups of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Community of Interest (COI). The ASBREM COI, formed under the authority of the Under Secretary of Defense for Research and Engineering, serves to facilitate coordination and prevent unnecessary duplication of effort within the Department of Defense's biomedical research and development community, as well as its associated enabling research areas. The cited research is consistent with the Under Secretary of Defense (Research and Engineering) Science and Technology (S&T) focus areas and the Army Modernization Strategy. The FY 2026 request was reduced by $0.059 million for Advisory and Assistance Services to promote efficiencies and advance the policies of the Administration in alignment with Executive Order 14222, "Implementing the President's Department of Government Efficiency Cost Efficiency Initiative." The FY 2026 request was reduced by $0.01 million for civilian personnel to optimize the workforce in compliance with Executive Order 14210, "Implementing the President's Department of Government Efficiency Workforce Optimization Initiative."

Mission — MEDICAL ADVANCE TECHNOLOGY INITIATIVES (CA) source

Congressional Interest Item funding for Medical Advanced Technology Initiatives. The cited work is consistent with the Under Secretary of Defense for Research and Engineering priority focus areas and the Army Modernization Strategy.

Mission — Enabling Med Cap to Support Dispersed OPS Adv Tech source

Matures and demonstrates a tele-monitored and remote-controlled Combat Evacuation Mission Module to support medical resupply and casualty evacuation using future multi-purpose Vertical Take-Off and Landing (VTOL) unmanned aircraft systems (UAS). Provides a self-contained medical module capability adaptable to various future multi- purpose VTOL UAS. Matures and demonstrates an intelligent decision-support capability that can be operated on an Army or Navy provided End User Device (EUD), such as the NETT Warrior system, to assist medics with patient assessment, triage, treatment, and disposition in a Prolonged Field Care (PFC) environment by assessing patient conditions to provide adaptive care guidelines.

Mission — Expeditionary Performance Nutrition Advanced Techn source

This Project covers the development of real-time, specific, and individualized interventions to optimize mental acuity and fatigue and manage metabolic and nutritional needs to sustain Soldier physical, mental, and immunological performance. The cited research is fully coordinated with Program element (PE) 0602143A (Soldier Lethality Technology) and complimentary to PE 0603118A (Soldier Lethality Advanced Technology) and is fully coordinated with other Services in order to avoid duplication of effort. The cited research is consistent with the Under Secretary of Defense (Research and Engineering) science and technology focus areas and the Army Modernization Strategy.

Mission — Phys Chem Toxicity Assessment Sys Adv Tech source

This Project covers the development of products and solutions that will protect and prevent degradation of Soldier health, readiness and performance from environmental stressors (heat, cold, altitude, and chemical toxicants) while conducting prolonged operations in Multi-Domain Operations (MDO). Develop algorithms and physiological models to inform unit leaders and Soldiers and provide actionable information and interventions to manage metabolic needs, maintain performance, and avoid non-battle injuries while operating in extreme environments. This Project contains no duplication with any effort within the Military Departments and includes direct participation by other Services. The cited research is fully coordinated with Program Element (PE) 0602143A (Soldier Lethality Technology) and complimentary to PE 0603118A (Soldier Lethality Advanced Technology). The cited research is consistent with the Under Secretary of Defense, Research and Engineering Science and Technology, focus areas and the Army Modernization Strategy.

Accomplishments & Planned Programs (10)